A Breakthrough for Thousands: Life-Extending Prostate Cancer Drug Now Available in England!
This is fantastic news for men in England battling prostate cancer. A crucial, life-extending drug, abiraterone, will soon be accessible to thousands, marking a significant victory for patients and advocacy groups. This decision comes after tireless campaigning and highlights the power of patient voices in healthcare.
Abiraterone, previously available in Scotland and Wales since 2023, will now be offered on the NHS in England to high-risk patients whose cancer hasn't spread. This expansion could potentially save hundreds of lives. The charity Prostate Cancer UK estimates that around 7,000 men a year will begin the treatment, with approximately 1,470 avoiding the progression of their cancer. Moreover, they anticipate that about 560 lives will be saved.
The drug works by starving cancer cells of the hormones they need to grow, effectively halting the spread of the disease. The NHS England anticipates the drug will be available within weeks, with around 2,000 men diagnosed in the last three months potentially gaining access if deemed clinically beneficial.
One man, Giles Turner, diagnosed with aggressive prostate cancer in March 2023, experienced firsthand the disparity in access. He was shocked and angered that his location denied him access to a treatment that could significantly improve his chances of survival. He started a campaign for change. He had to pay for the treatment himself, at a cost of £250 a month. He felt fortunate to afford it, but outraged that others could not.
But here's where it gets controversial... Despite the clear benefits, NHS England initially stated a lack of funding, a stance that was repeated by ministers. This led to a frustrating delay, with nearly three years passing before the policy change was implemented. Mr. Turner's persistence, however, ultimately paid off, leading to this momentous decision.
The effectiveness of abiraterone is backed by the STAMPEDE trial, published in 2022. The trial showed improved survival rates for men receiving the drug alongside standard care. The Institute of Cancer Research revealed that two years of abiraterone halved the risk of cancer recurrence and reduced the risk of death by 40%.
However, the path to approval wasn't smooth. The National Institute for Health and Care Excellence (NICE) had not initially approved the drug for newly diagnosed patients. But for NICE and the MHRA to consider extending a drug's usage they need detailed and time-consuming applications. Furthermore, the drug's patent expiration meant there was less incentive for companies to seek approval for a wider patient group. The shift in England was possible because of savings made on other medicines.
Professor Peter Johnson, National Clinical Director for Cancer at NHS England, emphasized the positive impact, stating that the treatment will give thousands of men a better chance at longer, healthier lives. Health and Social Care Secretary Wes Streeting echoed this sentiment, highlighting the importance of every day with loved ones and expressing delight at the NHS's action.
Professor Gert Attard, co-lead of the STAMPEDE trial, celebrated the news, emphasizing the life-saving potential of abiraterone when offered early. Prostate Cancer UK is now working to ensure similar access in Northern Ireland.
What are your thoughts on this? Do you believe the delay in access was justified? Share your opinions in the comments below!
